<DOC>
	<DOC>NCT00740584</DOC>
	<brief_summary>To assess the retention and anti-viral activity (human immunodeficiency virus (HIV) and herpes simplex virus 2 (genital herpes, HSV-2) of SPL7013 in cervicovaginal samples taken up to 24 hours after administration of 3% SPL7013 in the vagina. There is no hypothesis for this study.</brief_summary>
	<brief_title>Retention and Duration of Activity of SPL7013 (VivaGelÂ®) After Vaginal Dosing.</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Herpes Genitalis</mesh_term>
	<criteria>Healthy women aged 1845 with regular menstrual cycles, free from sexually transmitted infections and using adequate contraception Any condition, including genital conditions, sexually transmitted infection, menopause, and/or allergies that would make the study participant unsuitable for the study. Pregnancy or breastfeeding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Prevention</keyword>
</DOC>